Bortezomib

Generic Name: Bortezomib

Brand Names: Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₅BN_₄O_₄

CAS Number: 179324-69-7

Unique Ingredient Identifier: 69G8BD63PP

Background: Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is though...

Indication: Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.

Associated Conditions: Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)

Associated Therapies: -

Clinical Trials

Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

Phase 3

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Isatuximab
Drug: Lenalidomide
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2023-04-07

Last Posted Date: 2024-05-29

Lead Sponsor: University of Heidelberg Medical Center

Target Recruit Count: 514

Registration Number: NCT05804032

Locations: 🇦🇹
Phyrn-Eisenwurzen Klinikum Steyr, Steyr, Austria
🇦🇹
Universitätsklinikum der Paracelsus, 3. Med. Abteilung/Onkologie Ambulanz, Salzburg, Austria
🇩🇪
Charité, III. Medizinische Abteilung (Hämatologie/Onkologie), Berlin, Germany

and more 78 locations

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

Phase 2

Recruiting

Conditions: Thalassemia
Sickle Cell Disease
Thalassemia, Beta

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Tacrolimus
Drug: Mycophenolate Mofetil
Biological: Rabbit ATG
Drug: Dexamethasone
Drug: Bortezomib
Drug: Rituximab

First Posted Date: 2023-02-21

Last Posted Date: 2024-05-09

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 24

Registration Number: NCT05736419

Locations: 🇺🇸
Memorial Sloan Kettering Bergen (Consent only), Montvale, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Consent only), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering at Basking Ridge (Consent only), Basking Ridge, New Jersey, United States

and more 3 locations

GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5

Phase 2

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Daratumumab
Drug: Teclistamab (Tec)
Drug: Lenalidomide
Drug: Talquetamab
Drug: Dexamethasone
Drug: Bortezomib

First Posted Date: 2023-01-25

Last Posted Date: 2024-10-23

Lead Sponsor: University of Heidelberg Medical Center

Target Recruit Count: 130

Registration Number: NCT05695508

Locations: 🇩🇪
Charité University Medicin Berlin, Berlin, Germany
🇩🇪
Clinic Chemnitz gGmbH, Chemnitz, Germany
🇩🇪
University Clinic Technical University Dresden, Dresden, Germany

and more 8 locations

Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients

Phase 2

Recruiting

Conditions: Newly Diagnosed Multiple Myeloma

Interventions: Drug: Isatuximab
Drug: Lenalidomide
Drug: Bortezomib
Drug: Dexamethasone
Other: autologous stem cell transplant

First Posted Date: 2022-12-27

Last Posted Date: 2024-12-11

Lead Sponsor: University Hopsital Schleswig Holstein Campus Lübeck

Target Recruit Count: 100

Registration Number: NCT05665140

Locations: 🇩🇪
Heloisklinikum Berlin Buch GmbH, Berlin, Germany
🇩🇪
Klinikum Bielefeld - Onkologie, Hämatologie, Paliativmedizin, Bielefeld, Germany
🇩🇪
Universitätsklinikum Münster, Münster, Germany

and more 3 locations

The Investigate Efficacy and Safety Evaluation of Bortezomib in Patients With Relapsed/Refractory Immune Thrombocytopenia

Phase 2

Recruiting

Conditions: Relapsed/Refractory Immune Thrombocytopenia

Interventions: Drug: Bortezomib

First Posted Date: 2022-10-31

Last Posted Date: 2023-10-18

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 29

Registration Number: NCT05599880

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷
Seoul National University Bundang Hospital, Guri-si, Korea, Republic of

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

Phase 3

Recruiting

Conditions: Relapsed or Refractory Multiple Myeloma

Interventions: Drug: Teclistamab
Drug: Pomalidomide
Drug: Bortezomib
Drug: Dexamethasone
Drug: Carfilzomib

First Posted Date: 2022-10-07

Last Posted Date: 2024-12-06

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 650

Registration Number: NCT05572515

Locations: 🇺🇸
Michael E DeBakey VA Medical Center, Houston, Texas, United States
🇨🇦
Arthur J E Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
🇵🇹
Uls Gaia Espinho, Vila Nova de Gaia, Portugal

and more 205 locations

A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma, Mantle-Cell

Interventions: Drug: Ibrutinib
Drug: Lenalidomide
Drug: Rituximab
Drug: Bortezomib

First Posted Date: 2022-10-03

Last Posted Date: 2024-12-05

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 36

Registration Number: NCT05564052

Locations: 🇹🇷
Ondokuz Mayis University, Atakum, Turkey
🇧🇷
Santa Casa de Misericordia de Belo Horizonte, Belo Horizonte, Brazil
🇧🇷
Sociedade Beneficente de Senhoras - Hospital Sirio Libanes HSL Unidade Brasilia, Brasilia, Brazil

and more 63 locations

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

Phase 3

Recruiting

Conditions: Plasma Cell Myeloma

Interventions: Drug: Daratumumab and Hyaluronidase-fihj
Drug: Bortezomib
Drug: Dexamethasone
Drug: Lenalidomide
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2022-09-30

Last Posted Date: 2024-05-06

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 510

Registration Number: NCT05561387

Locations: 🇺🇸
Saint Luke's Cancer Institute - Twin Falls, Twin Falls, Idaho, United States
🇺🇸
Illinois CancerCare-Carthage, Carthage, Illinois, United States
🇺🇸
Saint Anthony's Health, Alton, Illinois, United States

and more 393 locations

NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide

Phase 3

Not yet recruiting

Conditions: Newly Diagnosed Multiple Myeloma

Interventions: Drug: Bortezomib
Drug: Isatuximab
Drug: Iberdomide
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2022-09-28

Last Posted Date: 2022-09-28

Lead Sponsor: PETHEMA Foundation

Target Recruit Count: 480

Registration Number: NCT05558319

Locations: 🇪🇸
Hospital Principe de Asturias, Alcalá de Henares, Madrid, Spain
🇪🇸
Hospital Germans Trias i Pujol (ICO BADALONA), Badalona, Spain
🇪🇸
Clinica Universidad Navarra (CUN), Pamplona, Navarra, Spain

and more 65 locations

A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Modakafusp alfa
Drug: Lenalidomide
Drug: Pomalidomide
Drug: Bortezomib
Drug: Carfilzomib
Drug: Daratumumab

First Posted Date: 2022-09-27

Last Posted Date: 2024-07-19

Lead Sponsor: Takeda

Target Recruit Count: 15

Registration Number: NCT05556616

Locations: 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Gabrail Cancer Center Research, Canton, Ohio, United States
🇺🇸
Scripps Health, San Diego, California, United States

and more 18 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy